Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas Short

Showing results (11-20 of 49) with videos related to

Pageof 5
Sort By:
Targeted Oncology|February 4, 2025
Checkpoint Inhibition Prior to Stem Cell Transplantation Increases the Risk of Inflammatory Adverse EventsMalek Shatila, Antonio Pizuorno Machado, Jay Shah, et al.
American Journal of Hematology|August 27, 2025
Contemporary Outcomes of Adults With Acute Lymphoblastic Leukemia With KMT2A Rearrangements Treated With Immunotherapy-Based RegimensHannah Goulart, Elias Jabbour, Nicholas Short, et al.
Haematologica|August 30, 2023
Myeloid lineage switch in <i>KMT2A-</i>rearranged acute lymphoblastic leukemia treated with lymphoid lineagedirected therapiesAlex Bataller, Tareq Abuasab, David McCall, et al.
Pathology|May 3, 2025
Acute lymphoblastic leukaemia with T- and B-lineage defining markersShuyu E, Fatima Z Jelloul, Karen A Nahmod, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 15, 2025
Allogeneic Hematopoietic Stem Cell Transplantation Following CAR T Therapy in Relapsed/Refractory Acute Lymphoblastic LeukemiaNatalie Rafaeli, David Marin Costa, Celina Ledesma, et al.
Annals of Hematology|March 21, 2018
Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemiaMaliha Khan, Tariq Muzzafar, Hagop Kantarjian, et al.
American Journal of Hematology|March 6, 2023
Outcomes of adult patients with relapsed/refractory CRLF2 rearranged B-cell acute lymphoblastic leukemiaSai Prasad Desikan, Jayastu Senapati, Elias Jabbour, et al.
Blood Neoplasia|January 15, 2026
Phase 1B pilot study of itacitinib with alemtuzumab in patients with T-cell prolymphocytic leukemiaTapan M Kadia, Akhil Jain, Caitlin R Rausch, et al.
Leukemia Research|May 14, 2024
Phase 1 study of azacitidine in combination with quizartinib in patients with FLT3 or CBL mutated MDS and MDS/MPNGuillermo Montalban-Bravo, Elias Jabbour, Kelly Chien, et al.
Blood Advances|August 30, 2023
Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemiaFarhad Ravandi, Asad Bashey, James Foran, et al.
Pageof 5

Showing results (11-20 of 49) with videos related to

Sort By:
Pageof 5
Targeted Oncology|February 4, 2025
Checkpoint Inhibition Prior to Stem Cell Transplantation Increases the Risk of Inflammatory Adverse EventsMalek Shatila, Antonio Pizuorno Machado, Jay Shah, et al.
American Journal of Hematology|August 27, 2025
Contemporary Outcomes of Adults With Acute Lymphoblastic Leukemia With KMT2A Rearrangements Treated With Immunotherapy-Based RegimensHannah Goulart, Elias Jabbour, Nicholas Short, et al.
Haematologica|August 30, 2023
Myeloid lineage switch in <i>KMT2A-</i>rearranged acute lymphoblastic leukemia treated with lymphoid lineagedirected therapiesAlex Bataller, Tareq Abuasab, David McCall, et al.
Pathology|May 3, 2025
Acute lymphoblastic leukaemia with T- and B-lineage defining markersShuyu E, Fatima Z Jelloul, Karen A Nahmod, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 15, 2025
Allogeneic Hematopoietic Stem Cell Transplantation Following CAR T Therapy in Relapsed/Refractory Acute Lymphoblastic LeukemiaNatalie Rafaeli, David Marin Costa, Celina Ledesma, et al.
Annals of Hematology|March 21, 2018
Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemiaMaliha Khan, Tariq Muzzafar, Hagop Kantarjian, et al.
American Journal of Hematology|March 6, 2023
Outcomes of adult patients with relapsed/refractory CRLF2 rearranged B-cell acute lymphoblastic leukemiaSai Prasad Desikan, Jayastu Senapati, Elias Jabbour, et al.
Blood Neoplasia|January 15, 2026
Phase 1B pilot study of itacitinib with alemtuzumab in patients with T-cell prolymphocytic leukemiaTapan M Kadia, Akhil Jain, Caitlin R Rausch, et al.
Leukemia Research|May 14, 2024
Phase 1 study of azacitidine in combination with quizartinib in patients with FLT3 or CBL mutated MDS and MDS/MPNGuillermo Montalban-Bravo, Elias Jabbour, Kelly Chien, et al.
Blood Advances|August 30, 2023
Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemiaFarhad Ravandi, Asad Bashey, James Foran, et al.
Pageof 5